Rhodes Jonathan K J, Sharkey John, Andrews Peter J D
University of Edinburgh, Department of Anaesthesia, Critical Care and Pain Medicine, Western General Hospital, Edinburgh, Scotland.
J Neurotrauma. 2009 Apr;26(4):507-25. doi: 10.1089/neu.2008.0686.
The expression of the neutrophil chemokine macrophage inflammatory protein-2 (MIP-2/CXCL2) and the monocyte chemokine monocyte chemotactic protein-1 (MCP-1/CCL2) have been described in glial cells in vitro but their origin following TBI has not been established. Furthermore, little is known of the modulation of these chemokines. Chemokine expression was investigated in male Sprague-Dawley rats following moderate lateral fluid percussion injury (LFPI). At 0, 4, 8, 12, and 24 h after injury, brains were harvested and MIP-2/CXCL2 and MCP-1/CCL2 levels measured by ELISA. To investigate the inhibition of chemokine expression a second cohort of animals received dexamethasone (1-15mg/kg), FK506 (1mg/kg), or vehicle, systemically, immediately after injury. These animals were sacrificed at the time of peak chemokine expression. A third cohort of animals was also sacrificed at the time of peak chemokine expression and immunohistochemistry performed for MIP-2/CXCL2 and MCP-1/CCL2. Following LFPI, chemokines were increased in the ipsilateral hemisphere, MIP-2/CXCL2 peaking at 4 h and MCP-1/CCL2 peaking at 8-12 h post-injury. Dexamethasone significantly reduced cortical MCP-1/CCL2, but not MIP-2/CXCL2 concentrations. FK506 did not inhibit chemokine expression. In undamaged brain, chemokine expression was localized to cells with a neuronal morphology. For MIP-2/CXCL2 this was supported by double staining for the neuronal antigen NeuN. In contused tissue, increased MIP-2/CXCL2 and MCP-1/CCL2 staining was visible in cells with the morphology of degenerating neurons. MIP-2/CXCL2 and MCP-1/CCL2 are increased after injury, and neurons appear to be the source of this expression. Chemokine expression was selectively inhibited by dexamethasone. The implications of this are discussed.
中性粒细胞趋化因子巨噬细胞炎性蛋白-2(MIP-2/CXCL2)和单核细胞趋化因子单核细胞趋化蛋白-1(MCP-1/CCL2)在体外神经胶质细胞中的表达已有报道,但它们在创伤性脑损伤(TBI)后的来源尚未明确。此外,对于这些趋化因子的调节了解甚少。在雄性Sprague-Dawley大鼠中度侧方流体冲击伤(LFPI)后,对趋化因子表达进行了研究。在损伤后0、4、8、12和24小时,采集大脑,通过酶联免疫吸附测定(ELISA)测量MIP-2/CXCL2和MCP-1/CCL2水平。为了研究趋化因子表达的抑制情况,另一组动物在损伤后立即全身给予地塞米松(1 - 15mg/kg)、FK506(1mg/kg)或赋形剂。这些动物在趋化因子表达峰值时处死。第三组动物也在趋化因子表达峰值时处死,并对MIP-2/CXCL2和MCP-1/CCL2进行免疫组织化学检测。LFPI后,同侧半球趋化因子增加,MIP-2/CXCL2在损伤后4小时达到峰值,MCP-1/CCL2在损伤后8 - 12小时达到峰值。地塞米松显著降低皮质MCP-1/CCL2浓度,但不降低MIP-2/CXCL2浓度。FK506不抑制趋化因子表达。在未受损的大脑中,趋化因子表达定位于具有神经元形态的细胞。对于MIP-2/CXCL2,这通过神经元抗原NeuN的双重染色得到证实。在挫伤组织中,在具有变性神经元形态的细胞中可见MIP-2/CXCL2和MCP-1/CCL2染色增加。损伤后MIP-2/CXCL2和MCP-1/CCL2增加,神经元似乎是这种表达的来源。地塞米松选择性抑制趋化因子表达。对此的意义进行了讨论。